Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp375 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

25-Hydroxyvitamin D values in liver transplant candidates

Monegal Ana , Peris Pilar , Cuervo Andrea , Muxi Africa , Gifre Laia , Guanabens Nuria

Introduction: Liver transplant candidates have bone and mineral metabolism disorders that may influence the development of fractures after liver transplantation (LT).Objective: To analyze the levels of 25-hydroxyvitamin D (25-OH-D) in patient candidates for LT and the factors associated with vitamin D deficiency.Methods: Between January 2010 and May 2012, 116 liver transplant candidates (85 male and 31 female patients) were include...

ba0002p76 | (1) | ICCBH2013

Final height and bone health in young adults, transplanted in childhood

Dyck Maria Van , Herman Jean , Lombaerts Rita

: This study analyses the long-term effect of rhGH on final height (FH) and bone health in renal transplanted patients.Twenty-one young adult patients, aged 17–26 years, were studied. Group A consisted of 15 patients (12 boys) who received rhGH during 3.0 years before transplantation. After transplantation three boys needed rhGH again for 3.5 years. In group B six patients (three boys) didn’t need rhGH before transplantation, three girls receiv...

ba0004op5 | (1) | ICCBH2015

Osteoclast phenotype of giant multinucleated cells in cherubism may determine the disease aggressiveness

Kadlub Natacha , Sessiecq Quentin , Lehalle Daphne , Badoual Cecile , Majouffre Claire , Berdal Ariane , Vazquez Marie-Paule , Descroix Vianney , Picard Arnaud , Coudert Amelie

Cherubism is a rare genetic disorder characterized by extensive growth of a bilateral granuloma of the jaws, resulting in facial disfigurement.Histologically, the lesions consist of a fibrotic stroma with osteoclastic-like multinuclear giant cells (MGC). Cherubism is caused by gain-of-function mutations in the SH3BP2 protein. SH3BP2 is an intracellular adaptor protein positively regulating the activity of the nuclear factor of activated T-cells c1 (NFATc...

ba0005p413 | Osteoporosis: treatment | ECTS2016

Dose postoperative applications of diphosphonate medicine at an early stage have influence on union of fracture?

Li Qiang , Zhang Jia , Zhu Shen

Background: Surgical and conservative treatments are both crucial method to deal with osteoporotic fracture, anti-osteoporotic therapy is the most important among conservative treatments and diphosphonate medicine is the first-line choice. The pharmacological action of diphosphonate medicine is to inhibit the function of osteoclast, so there is no consensus if it will inhibit porosis and union of fracture.Purpose: To find out the influence of diphosphona...

ba0007p174 | (1) | ICCBH2019

Supplementation of children with type 1 diabetes with milk or pharmacological calcium for improving bone health – a randomized controlled trial

Palande Sonal , Lohiya Nikhil , Mughal Zulf , Padidela Raja , Chiplonkar Shashi , Ekbote Veena , Khadilkar Anuradha , Khadilkar Vaman

Objective: Using DXA, we have previously reported that children with type 1 diabetes (T1D) had short and thin bones (Bone, 2015). Calcium supplementation promotes bone mass accrual with sustained benefit observed using milk/milk-based calcium but not calcium salts. To investigate effect of 1-year supplementation with milk vs pharmacological calcium salt on bone mineral density (BMD) and geometryin Indian underprivileged children with T1D. Both groups received vitamin D supplem...

ba0001oc6.4 | Mineralisation and energy metabolism | ECTS2013

Inhibition of PTH-induced vasorelaxation modulates its anabolic action

Gohin Stephanie , Chenu Chantal , Pitsillides Andrew , Arnett Timothy , Marenzana Massimo

The relationship between bone formation and blood flow is unclear. Recently, PTH was reported to activate production of nitric oxide (NO), a potent vasorelaxing agent, in endothelial cells and we and others have confirmed a strong vasorelaxing action of PTH in vivo in the mouse. Here, we tested the hypothesis that a potent NO synthase inhibitor (L-NAME: NG-nitro-L-arginine methyl ester) may alter the effect of intermittent PTH (iPTH) on b...

ba0003pp217 | Osteoporosis: evaluation and imaging | ECTS2014

An observational study investigating the prevalence of anaemia in hip fracture patients

Frankland Stuart , Gupta Abhaya

Introduction: The blood loss sustained during hip fracture repair can be significant and is associated with a high-risk of post-operative anaemia. Anaemia may exacerbate chronic cardiac and pulmonary conditions suffered by this aging population leading to increased morbidity and mortality.Objective: To assess the prevalence and severity of anaemia throughout hospital admission in patients admitted with a fractured neck of femur.Met...

ba0001s2.1 | Muscles and bone | ECTS2013

Skeletal muscle loss: sarcopenia and inactivity

McArdle Anne

Age-related loss of skeletal muscle mass and function is a major cause of loss of mobility, increased frailty and falls in the elderly and impacts profoundly on the quality of life of older people. Modified reactive oxygen species (ROS) generation has been implicated in the mechanisms by which muscle function is lost with increasing age. ROS are increased in skeletal muscles of adult mice following a period of isometric contractions and this is associated with adaptive increas...

ba0001pp131 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Effects of zoledronic acid on hormone levels in premenopausal women with breast cancer receiving neoadjuvant or adjuvant chemotherapy and endocrine therapy: Probone II Study

Hadji Peyman , Kauka Anette , Bauer Thomas , Ziller May , Birkholz Katrin , Baier Monika , Muth Mathias , Kann Peter

Introduction: Loss in bone mineral density may occur soon after initiation of adjuvant therapy for hormone-receptor-positive (HR+), breast cancer (BC) and correlates with changes in hormone levels. Adding zoledronic acid (ZOL) to adjuvant treatment for BC can preserve/improve bone mineral density and delay disease recurrence; however, effects of ZOL on endocrine hormone levels are currently unclear.Methods: Probone II assessed the course of endocrine hor...

ba0001pp225 | Cell biology: osteoclasts and bone resorption | ECTS2013

Inhibition of lipopolysacharide induced osteoclast formation and bone resorption in vitro and in vivo in mice by cystatin C

Fredrik Stralberg , Lindholm Catharina , Lindstrom Erik , Kasprzykowski Franciszek , Saftig Paul , Abrahamson Magnus , Grubb Anders , Lerner Ulf H

RANKL induced osteoclastogenesis is mediated by several transcription factors such as NF-κB, AP-1 and Nfatc1. We have found that also cysteine proteinases are involved in the signaling pathway downstream RANK. Thus, cystatin C, Z-RLVG-CHN2 (the sequence of which is based upon one of the enzyme inhibitory domains in cystatin C) and the fungal molecule E-64 – inhibit RANKL induced mouse and human osteoclast formation in vitro (Strålberg et ...